Cocrystal Pharma Company Insiders
| COCP Stock | USD 1.01 -0.06 -5.61% |
Cocrystal Pharma's insiders are aggressively buying. The analysis of insiders' sentiment of trading Cocrystal Pharma stock suggests that virtually all insiders are extremely bullish at this time. Cocrystal Pharma employs about 11 people. The company is managed by 4 executives with a total tenure of roughly 12 years, averaging almost 3.0 years of service per executive, having 2.75 employees per reported executive.
| Sam Lee Founder Co-Founder and Pres |
Insider Sentiment
Aggressively Buying
Selling | Buying |
Latest Trades
| 2026-02-06 | Phillip Md Et Al Frost | Acquired 50000 @ 0.95 | View | ||
| 2025-12-31 | Phillip Md Et Al Frost | Acquired 50000 @ 0.95 | View | ||
| 2025-12-30 | Phillip Md Et Al Frost | Acquired 20000 @ 0.97 | View | ||
| 2025-12-26 | Phillip Md Et Al Frost | Acquired 40000 @ 0.97 | View | ||
| 2025-12-24 | Phillip Md Et Al Frost | Acquired 25000 @ 0.97 | View | ||
| 2025-11-26 | Phillip Md Et Al Frost | Acquired 4000 @ 0.99 | View | ||
| 2025-11-25 | Phillip Md Et Al Frost | Acquired 20000 @ 0.94 | View |
Following insider trading sentiment in Cocrystal Pharma can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Cocrystal | Build AI portfolio with Cocrystal Stock |
Cocrystal Pharma Management Team Effectiveness
The company has return on total asset (ROA) of -45.77 % which means that on every $100 spent on assets, it lost $45.77. This is very low relative to industry peers. Similarly, it shows a return on stockholder's equity (ROE) of -94.94 %, which implies that shareholder value decreased during the period.As of 03/12/2026, Common Stock Shares Outstanding is forecasted to advance to approximately 12.3 M this year, whereas Net Loss is moving lower toward slightly above -36.7 M.
Cocrystal Stock Ownership Analysis
About 33.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cocrystal Pharma has Price/Earnings (P/E) ratio of 193.33. The company recorded a loss per share of 0.93. The firm last dividend was issued on the 24th of January 2018. Cocrystal Pharma completed a 1:12 stock split on 11th of October 2022.Cocrystal Stock Institutional Investors
Institutional ownership matters in Cocrystal Pharma because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Tower Research Capital Llc | 2025-09-30 | 3.3 K | Fortitude Family Office Llc | 2025-12-31 | 3.2 K | Wells Fargo & Co | 2025-09-30 | 1.8 K | Citigroup Inc | 2025-09-30 | 1.1 K | Northwestern Mutual Wealth Management Co | 2025-09-30 | 817 | Ubs Group Ag | 2025-09-30 | 571 | Clean Yield Group Inc | 2025-12-31 | 418 | Mccormack Advisors International | 2025-09-30 | 237 | Nvwm, Llc | 2025-12-31 | 84.0 | Vanguard Group Inc | 2025-12-31 | 264 K | Renaissance Technologies Corp | 2025-12-31 | 126 K |
Cocrystal Pharma Insider Trading Activities
Insider trading disclosures for Cocrystal Pharma offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 14.68 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Cocrystal Pharma Outstanding Bonds
Reviewing Cocrystal Pharma bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
Cocrystal Pharma carries a considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. The ownership breakdown for Cocrystal Pharma shows approximately 6% institutional, 33% insider, and 62% public. Shares in Circulation | First Issued 2007-09-30 | Previous Quarter 10.2 M | Current Value 11 M | Average Shares Outstanding 3.7 M | Quarterly Volatility 4.8 M |
Macro event markers
Cocrystal Stock Holders Distribution
Institutional ownership analysis for Cocrystal Pharma matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Cocrystal Pharma Market Cap and Value
Cocrystal Pharma Workforce Comparison
Cocrystal Pharma is rated below average. in number of employees category among its top competitors. The total workforce of Health Care industry is currently estimated at about 261. Cocrystal Pharma holds roughly 11.0 in number of employees claiming about 4% of equities under Health Care sector.
Cocrystal Pharma Insider Trading History
Insider trading disclosures for Cocrystal Pharma offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 14.68 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Cocrystal Pharma Notable Stakeholders
Stakeholders matter for Cocrystal Pharma because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Sam Lee | Co-Founder and Pres | Profile | |
| Roger Kornberg | Independent CoFounder | Profile | |
| Prof Kornberg | Independent CoFounder | Profile | |
| CPA CPA | CFO CoCEO | Profile |
About Cocrystal Pharma Management
Cocrystal Pharma is a micro-cap company in Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Leadership stability matters when evaluating execution against stated business priorities. CEO is CPA CPA with 11 employees and 4 reported executives. 
Gabriel Shpitalnik ยท Member of Macroaxis Editorial Board
Unless otherwise specified, financial data for Cocrystal Pharma is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Updates may occur throughout the day.
Cocrystal Stock is Curated By:
Gabriel Shpitalnik ยท Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Cocrystal Pharma can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Cocrystal Pharma Manpower Efficiency
Return on Cocrystal Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 4.4M | |
| Working Capital Per Employee | 832K | |
| Working Capital Per Executive | 2.3M |
Additional Tools for Cocrystal Stock Analysis
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |